All patients (n = 596) treated with PD-L1 or PD-1 inhibitor for advanced cancer between January 2017 and December 2021 were included.<h4>Results</h4>In total, 361 patients (60.6%) were classified as nonfrail and 235 (39.4%) as frail. This evidence concerns the gene CD274 and cancer.